ArticleHealth science reports2026
A Narrative Review on Integrative Bioinformatics Approaches for microRNA Research in Familial Mediterranean Fever: Current Insights and Future Directions.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Familial Mediterranean Fever (FMF) is a monogenic autoinflammatory disease caused by mutations in the Methods: A narrative review was conducted by examining published FMF studies that applied miRNA-focused bioinformatics analyses, including miRWalk, TargetScan, and machine learning pipelines. To identify tools with potential relevance to FMF, platforms widely used in rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, and psoriasis, such as miRDeep2, miRTarBase, DIANA-miRPath, miEAA, and MAGPIE, were evaluated for their analytical strengths and applicability to autoinflammatory pathways. Results: Most FMF studies rely on a narrow set of tools, primarily miRWalk or TargetScan for target prediction. Emerging machine learning approaches have also been utilized to classify patients and explore candidate biomarkers. Other inflammatory diseases use more advanced platforms enabling miRNA discovery, validated interaction mapping, pathway enrichment, and multi-omics integration. Tools such as miRDeep2, miRTarBase, DIANA-miRPath, miEAA, and MAGPIE remain underutilized in FMF. Key limitations include small cohorts, patient heterogeneity, and limited experimental validation. Conclusion: Broadening the bioinformatics toolkit for FMF miRNA research could significantly enhance biomarker identification and mechanistic insight. Larger datasets, integrated analysis pipelines, and cross-disciplinary collaboration are essential to advancing precision diagnostics and targeted therapies for FMF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.